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INTRODUCTION
Status Epilepticus (SE) is one of the most critical medical emergencies 
that  may result  in  significant  morbidity  and mortality  if  not  addressed in  a 
timely and effective manner1.  The approach in generalized convulsive SE is 
modified  by  changing  concepts  regard  the  definition  of  SE  and  studies 
justifying more aggressive treatment, with earlier intervention started prior to 
arrival to hospital. Currently SE has 1/5 the morbidity and 1/3 the mortality of 
pre -19702.  But still  mortality is around 11-53%  3,  4,  5.  Improvements reflect 
studies, retrospective data, changing definition of SE (from >60 minutes to > 5 
minutes). But most important factor is improved care. Although most seizures 
in children stop prior to arrival at a hospital, an estimated 60,000 US children 
are treated each year for SE. 1/3 of the episodes will be initial event in a patient 
with  new  onset  epilepsy  and  an  additional  third  occur  in  children  with 
established epilepsy. Up to 70% of children with epilepsy beginning before age 
1 will experience as episode of SE in their life time. Incidence is about 50000-
2.5 Lakhs times/year in US. 21% were <1year and 64% were <5 years. <50% 
of SE has h/o epilepsy. 15% of the epileptics will have SE at one time. 10% of 
the epileptics will present with SE at I time itself 2.
IMPORTANT CAUSES 
Acute causes:CNS  infections,  febrile  convulsions,  trauma,  metabolic 
derangements,  toxins,  drugs  overdose,  vascular,  hypoxia  etc.  Static  causes: 
Idiopathic  epilepsy  (here  SE  may  be  the  first  manifestation  or  may  be 
precipitated  by  drug  default  /poor  compliance,  irregular  drugs  sudden 
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withdrawal of AED, change of drugs, inadequate AED level in serum, fever, 
stress,  sleep  deprivation),  structural  brain  lesions  either  developmental  or 
acquired.   Progressive causes: Degenerative cerebral disorders. 
PATHOPHYSIOLOGY
SE is an emergency and must be treated immediately. Cardio respiratory 
dysfunction,  hyperthermia,  metabolic  derangements,  irreversible  neuronal 
injury can develop as a consequence of prolonged SE 9 . CNS injury can occur 
even when the patient is paralyzed with neuro muscular blockade but continues 
to have electrographic seizures6.
SEIZURE INITIATION AND PROLONGATION
Why seizures start and stop is unknown, although it is likely that seizure 
initiation  is  caused  by  an  imbalance  between  excitatory  and  inhibitory 
neurotransmission,  leading  to  the  initiation  of  abnormal  neural  impulses. 
Excitatory synapses mature earlier than inhibitory synapses and this, coupled 
with an increase in the susceptibility of excitatory neurotransmitter receptors, 
increases the likelihood that an excitation-inhibition imbalance may occur. 
The immature cerebral cortex has a high synaptic density at around 2 
months of age and this may contribute to the development of hyper synchrony 
of  neural  groups.  The  excitatory  amino  acid  neurotransmitter  glutamate 
increases at the site of the seizure focus at the beginning of seizure activity in 
adults with temporal lobe epilepsy. It is believed that the same may happen at 
the onset of generalized seizures. Inhibitory neurotransmitters such as GABA 
later increase at the seizure focus and redress the balance between excitation 
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and inhibition. Other mechanisms of inhibitory receptor modulation, such as 
adenosine receptor agonism, may also contribute to seizure termination. Thus 
the  increased  incidence  of  CSE  in  childhood  is  probably  caused  by  a 
combination of increased seizure susceptibility and decreased ability to mount 
an  adequate  inhibitory  response.  In  initiating  seizure  spread,  the 
synchronization of cerebral neurons is as important as neuronal discharge. The 
interconnections  between  the  thalamus  and  cerebral  cortex  are  essential  in 
forming  reverberating  circuits.  The  spike  and  wave  discharges  occur  when 
cortical neurons are depolarized (spike) or hyper polarized (wave).
ELECTROPHYSIOLOGY
About 70-80% of cases of CSE throughout all age groups will have a 
focal onset but be secondarily generalized. A predictable sequence of changes 
in the EEG has been shown in adult humans and in animal models. CSE starts 
with  localized  epileptic  activity  followed  by  isolated  generalized  bursts  of 
seizure activity with a normal EEG in between. If the patient does not regain 
consciousness between these episodes, then they meet the clinical criteria for 
CSE. The isolated ictal discharges merge and become a continuous discharge 
after about 30 minutes. Discharges then fragment and are interspersed with flat 
periods.  Ultimately,  periodic  epileptiform  discharges,  which  may  reflect 
underlying metabolic failure, will occur 7.
MOTOR RESPONSE
The motor phenomena associated with CSE follow a similar pattern to 
the EEG changes. Recurrent seizures will merge into continuous motor activity, 
followed by fragmentation of the motor activity and myoclonus. If the seizure 
persists,  then electromechanical  dissociation will  ensue. The prognosis for a 
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good neurological outcome decreases the further the patient moves through this 
continuum. 
ROLE OF EXCITOTOXIC AMINO ACIDS
They  are  important  in  causing  structural  brain  damage  secondary  to 
CSE.  Mesial  temporal  sclerosis  is  the  most  common  acquired  brain  lesion 
following CSE and may result from excitotoxicity. Most work in this field has 
been directed at the effects of glutamate. CSE can itself cause hippocampal 
damage  and  resulted  in  neuronal  loss  in  the  hippocampus,  neocortex, 
amygdala, thalamus, and cerebellum. Bilateral hippocampal damage may occur 
even with unilateral stimulation with excitatory neuro transmitters.
CSE  induces  the  production  of  heat  shock  proteins  in  several  brain 
regions.  The  presence  of  heat  shock  proteins  can  protect  the  brain  against 
further  stressful  stimuli,  which  are  potentially  damaging  to  neurons.  The 
implication is that prolonged seizures may need to occur in epilepsy human 
patients for mesial temporal sclerosis to develop, and that once it has developed 
further episodes of CSE may not worsen the mesial temporal sclerosis 8.  
MECHANISMS BY WHICH GLUTAMATE CAUSES CELL DEATH
Excess  extra  cellular  glutamate  may  result  in  cell  death  by  causing 
necrosis, gene determined cell death, or both. The primary receptor involved in 
cytotoxicity  related  to  glutamate  is  the  NMDA  receptor,  although  other 
glutamate  receptors  may  be  involved.  The  NMDA receptor  is  an  inotropic 
receptor. Influx of calcium through the ionophore occurs due to the binding of 
glutamate and glycine or D-serine to the appropriate site on the receptor. High 
intracellular calcium concentrations result in the activation of large number of 
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calcium dependent processes such as activation of protein kinase C, nitric oxide 
and free radical formation, activation of phospholipase A2 and activation of 
protease calpain I. 
Glutamate  receptor  stimulation  also  results  in  the  formation  of 
immediate early genes, such as c-fos, fos-B, c-jun, and jun-B, c-fos encodes for 
fos protein, which has a leucine zipper allowing it to bind and form dimers with 
similar  proteins.  These  dimers  bind  to  a  specific  DNA region  (AP-1  site), 
which regulates the expression of a number of late effector genes. Some of the 
genes  regulated are  harmful  and some are potentially  neuroprotective.  Thus 
immediate early genes may play a dual role in induction of gene determined 
cell death and activation of brain repair mechanisms. 
Patho physiological consequences following SE is extensively studied in 
animal models.  There is no deficit in brain energy state until later around 1 
hour,  when  parenchymal  oxygen  falls.  Then  brain  damage  occur9.  Several 
investigations have shown that seizures become more difficult to stop and the 
chances of neuronal injury increase when seizures persist beyond a transitional 
period  that  varies  between  20  and  60  minutes  in  animals  during  constant 
seizure activity. Treatment in children should be directed to supporting vital 
functions  and  to  controlling  the  convulsions  as  expeditiously  as  possible, 
because the precise transitional period in humans is not known.          
  
Prolonged seizures
Duration of seizure
Life 
threatening
systemic
changes
Death
Temporary
systemic
changes
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SYSTEMIC AND CENTRAL PATHOPHYSIOLOGY
The  systemic  effects  of  CSE  are  initially  dominated  by  the  body's 
attempt to maintain homeostasis. Blood pressure and central venous pressure 
increase,  blood glucose increases,  and the  patient  become tachycardic.  CSE 
may also  results  in  electrolyte  imbalance  and hyperthermia.  Cerebral  blood 
flow, blood glucose, and oxygen utilization increase in the initial phases of a 
seizure to maintain cerebral homeostasis.
After 30 minutes homeostatic failure begins and the patient may need 
systemic  support.  Cerebral  blood  flow,  brain  glucose,  and  parenchymal 
oxygenation  all  decrease  and  potentially  play  a  part  in  the  cell  damage 
associated with CSE. Respiratory and metabolic acidosis, electrolyte imbalance 
(for example, hyperkalemia), hyperthermia, and rhabdomyolysis may all occur. 
Treatment  with  drugs  with  depressant  cardio  respiratory  side  effects  (for 
example,  benzodiazepines  and  barbiturates)  may  worsen  the  systemic 
complications of CSE 9.
GLUCOSE
Initially hyperglycemia and in phase II become hypoglycemic.
Glucose
G
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Seizure duration
30 min
SE
SE + hypoxia 
Lothman E. Neurology 1990;40(5 .   Suppl 2):13-23..
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– Hyperglycemia
• Exhaustion phase
– Hypoglycemia 
develops
– Hypoglycemia 
appears earlier in 
presence of hypoxia
– Neuronal damage 
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HYPOXIA
Associated with SE is multi factorial. Impaired mechanical ventilation 
secondary to tonic clonic activity, increased salivation and tracheo bronchial 
secretions obstructing the airway, increased O2 consumption resulting from the 
seizure,  drugs  to  terminate  SE  are  respiratory  depressants  that  cause 
hypoventilation are some of the factors.
ACIDOSIS
Acidosis of SE is of both respiratory and metabolic in origin as seizure 
activity results in increased metabolic needs unmet by tissue oxygenation and 
perfusion, causing lactic acidosis.
Cerebral blood flow - Cerebral O2
requirement
Blood pressure 
Blood flow 
O2 requirement
Seizure duration
Hyperdyna
mic
Exhaustion
Lothman E. Neurology 1990;40(5 . l   Suppll
2):13-23..
• Hyperdynamic
phase
– CBF meets CMRO2
• Exhaustion phase
– CBF drops as 
hypotension sets in
– Autoregulation 
exhausted
– Neuronal damage 
ensues
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HEMODYAMICS
In first 30 minutes of seizure activity, catecholamine release results in an 
increase in heart rate, blood pressure, central venous pressure, cerebral blood 
flow and serum glucose. After 30 minutes of GTCS, Blood pressure begins to 
drop and cerebral blood flow although still increased above base line, drops to 
the point where it may be unable to supply adequate substrate and oxygen to 
meet increased cerebral metabolic demands. This results in impaired cortical 
oxygenation 9. Other effects are ↑ CPK, Myoglobinuria, ATN, trauma, tendon 
rupture. Seizure duration greater than 1 hour, especially with hypoxia, has been 
associated with permanent neurologic injury.
BP
During SE cerebro vascular resistance falls due to hypoxia resulting in 
severe derangement of cerebral auto regulation. Cerebral perfusion becomes 
directly dependent on systemic blood pressure. Within the first 30 minutes of 
SE  hypertension  occurs.  Later,  BP  either  becomes  normal  or  low.  This 
Hemodynamics
• Sympathetic 
overdrive    
– Massive catecholamine / 
autonomic discharge
– Hypertension
– Tachycardia
– High CVP
• Exhaustion
– Hypotension
– Hypoperfusion
0 min 60 min 
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circulatory  shock  which  follows  ongoing  SE  severely  deranges  cerebral 
physiology.
ALTERED MENTAL STATUS /NCSE
Convulsions are easily identified as the source of altered mental status if 
typical  tonic  clonic  movements  are  witnessed.  However,  children  may  also 
present in a post ictal state, without a clear history of a seizure, thus making the 
diagnosis more difficult to determine. Further more, seizures may be followed 
by a period of transient paralysis (Todd’s paralysis) that is often present on one 
side of the body. This may lead to the clinician to suspect a structural etiology 
rather than seizures. NCSE should be considered in comatose children without 
signs of seizures activity, an EEG, will help to diagnose this condition11.
NCSE
If  the  patient  stops  overt  convulsions  yet  remains  comatose an  EEG 
should be performed to rule out ongoing S.E. Up to 20% of children with SE 
have  non -  convulsive  SE after  tonic  -  clonic  SE12.  Neurologic  signs  after 
termination of SE are common: pupillary changes, abnormal tone, abnormal 
Babinski reflex, posturing, clonus, may be asymmetrical.  They should not be 
misinterpreted as NCSE. 
NCSE  is  commonly  diagnosed  in  children,  where  as  acute  delirium 
status is frequent in adults ED diagnoses. NCSE is usually entertained only 
when the child is unresponsive and rigid or has a known seizure disorder. But 
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PCSE and ASE both can present with subtle findings erroneously ascribed to 
other etiologies and may occur in patients with out a known seizure history13.
NCSE accounts for almost 20% of SE 13. PCSE has been associated with 
neuronal damage and stroke14  and is more likely caused by primary pathology 
of the cortex such as an infection or bleed. In contrast ASE probably has a 
different and less harmful origin, seemingly resulting from vacillating thalamo 
cortical excitation and excessive synchronous neuronal inhibition, which could 
explain the absence of tissue injury following its resolutions14. In PCSE, as in 
GTCS excessive excitatory  neuro transmitter  release  leads  to  depolarization 
and increased intracellular calcium. When GABA inhibition is overwhelmed, 
calcium triggered proteases and lipases leads to cell injury and death14.     
REFRACTORY STATUS EPILEPTICUS
RSE is defined as seizures that do not controlled with adequate does of 
BZD,  Phenytoin  or  Phenobarbital  and  require  more  aggressive  treatment15. 
Complications are more and out come poor in RSE. Continuous IV infusions of 
anesthetic doses of midazolam, propofol,  or barbiturates are the most useful 
treatments16. Children with prior, new, progressive CNS injury are more prone 
to have RSE.
TYPES OF SE7
Convulsive SE (CSE)
GCSE/ GTCS (primary)
Secondary generalized
Multifocal clonic
            Hemi convulsive SE
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Tonic SE
Clonic SE
Simple PSE/ Epilepsia partia continualis
Non convulsive SE (Subtle SE) 
Neurological EMD (Electrical SE)
PCSE
ASE
Myoclonic SE +/- salaam attacks
INITIAL INVESTIGATIONS
 Blood - glucose, calcium, electrolytes
Blood counts
CXR
USG Cranium / CT Brain
CSF analysis
EEG
OTHER INVESTIGATIONS SUGGESTED
RFT
LFT
Magnesium
ABG
Septic work up (Cultures)
Blood / Urine - AED levels
Toxicological screening 
Metabolic screening
X ray skull
MRI
Lactate, NH3
MEDICAL COMPLICATIONS OF STATUS EPILEPTICUS
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STATUS INDUCED
Epilepsy subsequently (77%)
Hemi convulsion Hemiplegia (HH)
Hemi convulsion Hemiplegia Epilepsy (HHE)-rare now
INTER ICTAL COMA
CUMULATIVE ANOXIA 
Cerebral and systemic
CARDIO VASCULAR COMPLICATIONS
Tachycardia, Bradycardia
Cardiac arrest
Hypertension, Hypotension
Cardiac failure,
Cardiogenic shock
RESPIRATORY SYSTEM FAILURE
Apnea
Chyne stokes breathing
Bradypnea, 
Tachypnea
Neurogenic pulmonary edema
Aspiration pneumonia
Respiratory acidosis 
Cyanosis
RENAL FAILURE
Oliguria
Uremia
ATN
Rhabdo myo lysis
AUTONOMIC SYSTEM DISTURBENCE
Hyperpyrexia
Excessive sweating, vomiting 
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Hyper secretions (salivary, tracheo bronchial)
Airway obstruction
METABOLIC AND BIOCHEMICAL ABNORMALITIES
Acidosis (metabolic, lactate), Anoxemia
Hypernatremia, Hyponatremia
Hyperkalemia
Hypoglycemia
Hepatic failure 
Dehydration
Acute Pancreatitis
Leucocytosis
INFECTIONS    
Pulmonary 
Urinary
Skin
OTHERS 
Altered auto regulation of CBF 
Increased cerebral metabolic rate of O2 (CMR O2)
DIVC
MODS
Fractures
Thrombo phlebitis 
MANAGEMENT
Longer the duration of seizures, greater the risk of complications, so, 
every  attempt  should  be  made  to  control  epileptic  activity  (clinically  and 
electrically).  Status  Epilepticus  is  a  medical  emergency  that  requires  an 
organized  and  skillful  approach  to  minimize  the  associated  mortality  and 
morbidity.  Convulsive  Status  Epilepticus  is  one  of  the  most  critical  neuro 
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emergencies  and  every  physician  confronted  with  these  patients  in  the 
emergency  department  should  have  a  protocol  in  mind  how  to  terminate 
seizure.  Therapy  must  be  aggressive  because  neuronal  excitability  can  be 
reversed only early in the course and quick intervention may decrease the risk 
of seizures generated neuronal damage. 
 The  longer  SE  persists,  the  lower  is  the  likelihood  of  spontaneous 
cessation, the harder it is to control and the higher is the risk of morbidity and 
mortality16. GCSE is a condition which most likely will not terminate rapidly 
and / or spontaneously and requires prompt intervention17. Primary aim is to 
control  and  abort  SE  as  the  duration  of  seizure  activity  is  directionally 
proportional to immediate mortality and later morbidity. Goal of treatment is 
the cessation of both clinical and electrical seizures. A time framed protocol is 
essential in the management of SE in Emergency Room. 
 Goal  of  management  is,  to  maintain  adequate  vital  function  and 
oxygenation, to terminate seizure activity as quickly as possible, to evaluate 
and treat the underlying cause of SE. Ventilation is to be anticipated. Use of 
ACDs  to  stop  seizures  and  to  stop  respiration  for  intubation  is  better  than 
giving neuromuscular blockade alone.  Use correct  and adequate anti-seizure 
drug doses. Epileptics and non-epileptics in status require the same drug doses. 
It should be remembered that outcome is determined by etiology, age, duration 
and treatment. We can affect only the treatment. Most easily missed causes of 
status  epilepticus  are  bacterial  meningitis,  encephalitis,  abuse/unsuspected 
trauma, drug ingestion. 
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Priority  is  the management of ABCs along with rapid termination of 
seizure activity. Benzodiazepines are the initial drug of choice in terminating 
SE. Lorazepam, Diazepam, Midazolam are the recommended drugs. Though 
diazepam and lorazepam are equally effective in controlling seizures lorazepam 
is preferred because if it’s longer duration of action 18, 19. If diazepam is given it 
should be followed by a long acting drug ACD such as phenytoin to prevent 
recurrences 110. Midazolam has no more advantage over diazepam or lorazepam 
in efficacy, onset and duration but can be given as IM injection. So, ideal for 
pre hospital therapy and it can be given if IV access could not be obtained 20, 21. 
Intramuscular midazolam is given as 0.2 mg/kg and it is an aqueous solution 
and  rapidly  absorbed,  anticonvulsant  effect  begins  after  2  minutes. 
Intramuscular lorazepam also can be given, but lacks water solubility, thus later 
onset than midazolam. 
Phenytoin is given as 20 mg/kg I.V. over 20 min, then if needed 10 mg / 
kg IV infusion over 20 min. Its pH is 12, extravasations cause severe tissue 
injury. Onset is 10-30 min and may cause hypotension, arrhythmias, ventricular 
standstill 22- 30 but cheap.
 Fosphenytoin is a newer pro drug of phenytoin. Given as 20 mg PE/kg 
IV over 5-7 min, PE = phenytoin equivalent, pH 8.6, extravasations are well 
tolerated.  Onset  is  5-10  min,  may  cause  hypotension,  but  less  and  it  is 
expensive  31-40.  The main difference between phenytoin and fosphenytoin in 
children is the pH. Fosphenytoin will not cause the severe tissue damage seen 
with  phenytoin  in  case  of  infiltration.  If  in  doubt  about  serum  level  free 
phenytoin is to be measured. Phenytoin is largely protein bound. (> 90%, varies 
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with  serum  protein  concentration).Free  phenytoin  =  active  phenytoin 
(anticonvulsant  and  toxic  effects).  Toxicity  is  more  likely  with  hypo 
albuminemia (usually if < 2 g/dl). Therapeutic levels: Total phenytoin: 10 - 20 
mcg/ml, Free phenytoin: 0.8 - 1.6 mcg/ml
 In RSE, midazolam given as 0.2mg/kg IV bolus followed by 0.75 to 10 
mcg/kg/min infusion 41-45. Propofol is given as 1to2 mg/kg loading followed by 
2  to  10  mg/kg/hr  46-50.  Both  drugs  have  the  substantial  advantage  over 
barbiturates of rapid clearance and midazolam has less pronounced hypotensive 
effects. Midazolam infusion is typically maintained for 12 to 24 hours and is 
then withdrawn gradually while the patient is observed for clinical and EEG 
evidence  of  seizure  termination.  If  seizure  continues  the  therapy should  be 
resumed  for  prolonged  periods.  Midazolam  may  be  associated  with 
tachyphylaxis leading to the need for exceedingly high doses. Propofol is a pro 
convulsant. Seizure during induction and termination was reported but, these 
effects in the management of SE are unknown. 
Thiopental  and  pentobarbital  are  potent  anti  seizure  drugs  that  have 
potential though unproved cerebral protective effects in the management of SE 
51-59.  In  adequate  doses  these  drugs  will  always control  seizures,  but  severe 
hypotension requiring pressor therapy limits their safety. So, these are reserved 
for failed midazolam / propofol. In resistant cases, Inj. Sodium valproate 20-40 
mg/kg IV bolus as infusion may be used 60-78.
EEG
In a child with a new onset of seizures, an EEG may help to differentiate 
ictal from non ictal events, to determine seizures type or epilepsy syndrome 
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and to better define the risk for recurrence. For most children it is not necessary 
to perform the EEG as part of the initial emergency department evaluation. In 
fact if it is performed shortly after the seizure (<48 hours) the EEG may show 
diffuse  post  ictal  slowing  without  prognostic  significance  79,  80,  81.  Among 
children with persistent altered mental status after a seizure an emergent EEG 
is helpful to identify subtle or NCSE 82.
NEURO-IMAGING: CT Brain may be necessary to evaluate safety of 
LP and to rule out hemorrhage or large mass lesions. MRI will almost always 
be performed later, even if CT is normal.
LP : LP should be done if SE presented in febrile children. And it 
should be done only after stabilizing the child not at arrival. 
OUTCOME 
Outcome  is  determined  by, Etiology,  Age,  Duration,  Treatment3,  4,  5. 
Ultimately mortality related to, damage to the CNS caused by the acute insult 
precipitating  SE,  systemic  stress  from SE (major  cause  because  of  anoxia, 
acidosis,  shock),  injury  from repetitive  epileptic  discharges  within the  CNS 
(minor but cognitive impairment later). Mortality increases from 3% to 32% if 
the duration of seizures becomes >1 hour.
Etiology Risk of Epilepsy
Risk of 
Recurrence
Chronic AED 
Rx
Idiopathic 0% 3% No!
Remote symptomatic ++ 50% Yes!
Febrile + + No?
Acute Symptomatic 15-30% + Yes?
Progressive ++ 50% Yes!
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Normal  children  and  children  with  febrile  status  have  a  favorable 
prognosis. Improved outcome is a result of timely and approximate evaluation 
and treatment. Most favorable for patient who respond to first line agents, but 
obviously  the underlying cause of status,  determine the outcome. Cognitive 
function may be impaired (particularly  memory) in  patients  with prolonged 
S.E. and is more common when significant hypoxemia (aspiration) intervened. 
Out come may be worse when S.E. is managed inappropriately. Most common 
mistakes seen are,  inadequate dosing,  Failure to order maintenance therapy. 
Failure  to  do  the  latter,  results  in  recurrence.  AED  should  be  continued 
particularly if a structural lesion resulted in S.E.
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Kwong RL et  al  83:   Features  predicting  adverse  outcome of  SE in 
children. OBJECTIVE:   To examine  variables  that  might  predict  abnormal 
outcome of SE among children.   DESIGN:  Retrospective study. SETTING: 
Regional Hospital, Hong Kong. INCLUSION : < 15 Years admitted in PICU 
1997  –  2002.  MAIN  OUTCOME:  Neuro  developmental  out  come. 
OBSERVATION: 2/25 died (8 %). No patient with febrile seizure or idiopathic 
SE  developed  neurological  deterioration.  6/23(25%)  symptomatic  (acute  & 
remote), refractory SE associated with poor outcome. Young age <12 months 
and duration >60 minutes associated with adverse outcome. Rectal diazepam 
only in 4 as pre hospital theraphy. CONCLUSION: Pediatric patients who had 
normal neuro developmental status before SE and who did not sustain an acute 
insult to the CNS or have progressive encephalopathy had favorable out come. 
Pre hospital treatment with BZD reduces adverse outcome. 
Garzon E  84:  Analysis  of  clinical  characteristics  and risk factors  for 
mortality in human status epilepticus. OBJECTIVE: To analyze clinical data 
including  etiology,  age,  antecedents,  classification  and  mortality  in  human 
status epilepticus, and to assess prognostic factors for mortality. A prospective 
study was performed, including detailed analysis of clinical  and laboratorial 
data of SE in individuals of any age, except neonates. SETTING: Department 
of  Neurology  and  Neurosurgery,  Federal  University  of  Sao  Paulo. 
OBSERVATION: 111 SE were included with patient’s  age ranging from 3 
months to 98 years. SE incidence peaked in the first years of life, and 59.4% of 
the  individuals  had  pervious  epilepsy  while  40.6%  had  not.  The  main 
underlying causes were noncompliance to treatment in the first group and CNS 
infection,  stroke  and  metabolic  disturbances  in  the  second  group.  Overall 
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mortality was 19.8% and deaths were correlated to etiology and patient’s age. 
Refractory SE affected 11.7% of the cases. CONCLUSION: Epileptic patients 
are at greater risk to develop SE, however, individuals with no prior history of 
epilepsy and acute neurological problems can also present with SE. Etiology 
varies  with  patient’s  age,  and  mortality  is  high  and  related  to  age  and 
underlying  causes.  Clinical  and  clinico-electrographic  classifications  are 
usually  convergent,  but  in  some  cases  the  diagnosis  of  SE  would  not  be 
established without the EEG.
Towne AR et al  85:   Determinates of mortality  in  status  epilepticus. 
Using univariate and multivariate regression analysis, seizure duration, seizure 
type, age, etiologies, other clinical features and mortality were studied among 
253 adults with SE admitted to the Medical College of Virginia. SETTING: 
Department  of  Neurology,  Medical  College  of  Virginia,  Virginia. 
OBSERVATION: CVA and discontinuation of AED were the most prominent 
causes of SE each accounting for approximately 22 % of all  patients in the 
series.  The  other  principle  etiologies  were  alcohol  withdrawal,  idiopathic, 
anoxia, metabolic disorders, hemorrhage, infection, tumor, drug overdose and 
trauma. When the patients were divided into two groups, the group with SE 
lasting <1hr had a lower mortality as compared with seizure duration > or = 1 
h.  Low  mortality  rates  were  noted  in  alcohol  and  AED  discontinuation 
etiologies. Anoxia and increasing age were significantly correlated with higher 
mortality.  The  mortality  rates  of  partial  and  generalized  SE  were  not 
significantly  different.  Race  and  sex  did  not  affect  mortality  significantly. 
CONCLUSION:  These  findings  represent  the  first  multivariate  analysis  of 
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predictive indicators of mortality in SE and demonstrate that specific factors 
influence mortality rate in SE.
Veryty  CM et  al  86: Outcome  of  SE  & lengthy  FSE:   Findings  of 
National Cohort Study. OBJCTIVE: To study out come after a lengthy FSE & 
SE  in  children.  DESIGN:  Population  based  birth  cohort  study.  SETTING: 
Child  health  and  education  study.  (16004  neonatal  survivors  born  in  April 
1970),USA.  14676  –  Information  available.  OBSERVATION:  Clinical 
information and tests of intellectual performance at 5 years and 10 years after 
birth.19 had lengthy FSE, 18 had SE.  2SE died, but not due to it. 4/19 FSE 
(21%) developed seizures. Intellectual performance: 23 normal, 10 abnormal (8 
preceding  developmental  delay,  neurologic  abnormality).CONCLUSION: 
Outcome is better that reported from studies, seems determined more by the 
underlying cause than by seizures themselves.
Sahin et al  87: Mortality in RSE was related to etiology age and EEG 
findings.  Higher  is  younger  children  and  with  multi  focal  or  generalized 
abnormalities on the initial EEG. 
Hui AC, et al 88: Factors of poor outcome, defined as death or morbidity 
as measured by deterioration in functional status using the Glasgow outcome 
score were analyzed in a multivariate logistic regression model.  There most 
common  causes  were  CVA,  metabolic  derangements  and  anticonvulsant 
withdrawal in adult population. 26% had worst functional ability, and mortality 
rate was 26%. Predictors of poor outcome were older age (OR = 1.04, 95% CI 
1.01 – 1.07), delay in treatment (OR = 9.73, 95% CI 1.58 – 59.96) and CNS 
infection 9 OR = 30.27 95% C 3.14-292.19).
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Mah JK, Mah MW  89: King Khalid national guard hospital,  Jeddah, 
kingdom of SA. Pediatric SE: Perspective from Saudi Arabia. Objective: To 
assess  risk  factors  and management  of  SE and  non SE  seizures.  DESIGN: 
prevalence study of a convenience sample of pediatric seizure admitted from 
1992 to 1997. RESULT: Mean age 2year 4month. 43% no prior seizures. 28% 
(59) of 212 seizures were SE. SE more than non SE in cases with h/o seizure, 
AED,  acute  etiology.  CONCLUSION:  Management  of  SE  in  this  referral 
population can be improved by more rapid access to appropriate medical care.
Dunn DW  90:  SE in children: etiology, clinical features and outcome. 
Indiana  university  school  of  medicine.Indianapolis-46202.Aug  1984  to  sep 
1986  prospective  case  series  data-  114  episodes  of  SE.  RESULTS: 
Symptomatic 72% (chronic59%,acute 13%) . Idiopathic or Febrile - 28%. 63% 
-precipitating factors present. Most common factor – inadequate blood levels of 
ACD (32/60 with h/o prior  fits).  Febrile  illnesses excluding CNS infections 
(38/114).  8 died, 3 with pre existing brain damage,2 with meningitis,2 with 
poorly defined encephalopathy. 18 developed new neurological deficit  (5 in 
idiopathic or febrile SE group. 13 in symptomatic SE group). Outcome related 
to etiology, duration, and age is a minor factor.
Allredge  BK,  Wall  DB,  Ferriero  DM  91:   Effect  of  pre  hospital 
treatment  on    the  outcome  of  SE  in  children.  University of California, 
Sanfrancisco. USA. Review of cases. Clinical course of 45 episodes of GCSE 
evaluated.  OBJECTIVE:  To  determine  the  effect  of  pre  hospital  Diazepam 
therapy (IV/PR), given by paramedics in many EMS systems throughout USA, 
on  the  clinical  course  of  SE  and  subsequent  patient  management. 
OBSERVATIONS: 19 cases  had pre  hospital  therapy.9 PR.  Mean dose 0.6 
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mg/kg.10 IV. Mean dose: 0.2mg/kg. Pre hospital therapy was associated with 
shorter duration of SE (P=0.007), reduced likelihood of recurrent seizures in 
ER (P=0.045).no significant difference between PR and IV. CONCLUSION: 
Pre hospital administration of diazepam shorter the duration of SE and simplify 
the subsequent management of these patients.
Simon  J.  Parsons,  Katarina  Tomas,  Peter  Cox  92:  Out  come  of 
Pediatric Status Epilepticus Admitted to Intensive Care:  The authors determine 
the relationship between seizure duration, etiology, and outcome in a modern 
intensive care setting and assess the usefulness of computed tomography (CT) 
and the empiric use of antimicrobial therapy. The design was a retrospective 
chart  review.  The setting was a  tertiary  pediatric  critical  care  unit.  Patients 
included 161 consecutive admissions to the critical care unit at the Hospital for 
Sick  Children,  Toronto,  with  status  epilepticus  over  a  3-year  period.  There 
were  no  interventions.  The  overall  mortality  was  5.6%.  A  further  11% 
experienced  an  adverse  neurological  outcome  as  determined  on  hospital 
discharge. Mean seizure duration was 1.5 ± 2.8 hours in those children with a 
normal  outcome,  1.7  ±  1.2  hours  in  those  survivors  with  an  abnormal 
neurological outcome (P > 0.05), and 6.8 ± 12 hours in those who died (P < 
0.05). The CT scan was abnormal in 41% of cases. New findings that directly 
affected immediate management decisions were found in 20% of CT scans. 
Both the duration and etiology of status epilepticus affect  the outcome. CT 
scanning should be done without delay, once the patient is stable.  Antiviral 
therapy should be started empirically now that encephalitis is far more common 
than  bacterial  meningitis  in  this  group  of  patients.  Studies  are  lacking  that 
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compare the efficacy of drugs available to treat status epilepticus. These studies 
need to be done, as the findings could affect the duration of status. 
Murthy  JM,  Yangala  R  93.  Nizam’s  institute  of  medical  sciences, 
Hyderabad. Acute symptomatic seizures incidence and etiological spectrum. A 
hospital based study done in Nizam’s Institute of Medical Sciences considered 
that etiological spectrum of acute symptomatic seizures in this part of the world 
is different from that described from developed countries and CNS infection 
account for a significant number of cases.
Singhi  S,  Singhi  P,  Dass  R  94. Advanced pediatric  center  PGIMER. 
Chandigarh. SE: emergency management. SE is a medical emergency and need 
prompt and aggressive management. In children mortality from SE ranges from 
3-10% and morbidity is twice. Morbidity and mortality are highest with SE that 
associated with CNS infections which is the most important cause of SE in our 
country. The outcome depends on the underlying etiology, age, rapidity of SE 
and adequacy of care. Adherence to a time framed protocol in the ED helps in 
improving the final outcome.
Santhosh  Paulin  95.  ICH  and  HC,Chennai.  Clinical  profile  of 
convulsive RSE in children. OBJECTIVE: To assess the incidence, common 
causes,  complications,  outcome  of  RSE  in  children  and  efficacy  of  IV 
midazolam infusion in controlling RSE.A descriptive study conducted in PICU 
of ICH from April2002 to Mar2003.RESULTS: 26 cases of RSE among 418 
SE cases. male=female. mean age of 3 years with range from 1 month to 12 
years.65% needed midazolam of <6 mcg/kg/min. Mean duration for control of 
seizure 3hr56min.recurrence on  tapering noted only in two cases. mean dose 
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12.5 mcg/kg/min.8/26 had shock recurrence after midazolam infusion.53% on 
midazolam needed ionotropes, mean duration of midazolam  was 2days and  7 
hours. Death 35%  and 19% had neurological sequele, 46% recovered. Acute 
CNS infection commonest cause. CONCLUSION:  Midazolam infusion is safe 
and effective in controlling RSE and can be used in the management of RSE. 
High mortality in that study was due to CNS co morbid conditions.
Eelco F.M, Wijdicks  96:  Medical online review and data base on SE, 
Neurological  ICU.  Saint  Mary’s  hospital.  SE  categorized  into  5  classes. 
Convulsive SE (tonic clonic SE),non convulsive SE, myoclonic SE, focal SE, 
psychogenic SE. Therapy must be aggressive because neuronal excitability can 
be reversed only early in the course and only quick intervention may decrease 
the  risk  of  seizure  generated  neuronal  damage.  Seizures  commonly  ceases 
within 5 minutes.
Kalra  Veena  et  al  97: OBJECTIVE:  To  study  the  clinical  profile 
immediate outcome and possible risk factors of SE in Children admitted in 
PICU.  DESIGN:  Retrospective,  study  of  case  records.  SETTING:  AIIMS; 
PERIOD: 451 Neuro emergencies between Jan 1993 to April 2000.in children 
in a tertiary care center. –30 had SE. INCLUSION: 30 SE Cases. RESULTS: 
Age: 1- 120 months.Mean  56.6  ±   46.5  months.  17  patients  were  <  60 
months.16 patients (53.3%) had SE I episode with out prior H/o fits.9 (30%) 
died during hospital course. Seizure duration >45 min (p.0.001) and presence 
of septic shock (p-0.001) were associated with significantly more mortality. 
CONCLUSION: There is a need to abort seizure activities at the earliest to 
improve immediate outcome. 
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Maytal J et al  98:  In an ongoing study of SE, 193 children with SE of 
varying causes have been followed up for a mean period of 13.2 months. Of 
those 97 were recruited prospectively. The patient’s ages range from 1 month 
to 18 years. Mean - 5 years. The cause of SE was classified as idiopathic in 46 
cases, remote symptomatic in 45, febrile in 46, acute symptomatic in 45, and 
progressive neurologic in 11. 7 died and new neurologic deficits were found in 
17 (9.1%) off the 186 survivors. All of the deaths and 15/17 sequele occurred 
in  acute  and progressive neurologic  insults  group.  Only  2/137 other  causes 
sustained any new deficits  (p<0.001).  Duration of  SE affects  outcome only 
with in  the  acute  symptomatic  group.    Sequele  occurred mostly in  infants 
(29%) and 11% in 1-3 years group, 6% in > 3 years. 61 had prior unprovoked 
seizures (32%). 
Sahin M et al  99:  out come of severe RSE in children. Epilepsia 2001 
Nov: 42(11)1461-7. OBJECTIVE: out come of RSE in children. Retrospective 
review  of  case  records  between  1992-2000.children’s  hospital,  Boston, 
Massachusettes,USA. Factors evaluated age, etiology and initial EEG findings 
including mortality or return to baseline. RESULTS: 22 patients 4.5 months to 
18 years treated for < or = to 146 days .Mortality 7/22(31.8%) related to age, 
etiology and initial EEG findings. None return to base line. No death in remote 
symptomatic group.3/4 younger than 3 years died.4/18 older than 3 years died. 
Focal abnormalities in EEG are associated with less mortality than multifocal 
or  generalized abnormalities.  CONCLUSION: High mortality and morbidity 
for childhood RSE is demonstrated.  
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Horn drop: Study observed that symptomatic SE and refractory SE and 
associated with poor outcome than idiopathic or febrile SE and young age < 12 
months duration of seizure > 60 minutes are associated with adverse outcome. 
Etiology Of Status (Children)100: Fever – 36% (non –CNS infection), 
idiopathic - 24 – 39%, chronic  neurological  disease-  15%,  metabolic 
/toxic- 8%, medication change -20%, anoxia -5%, CNS  Infection 
-5%,tumor -1%,  acute trauma / abuse - 4%, degenerative disease- 2%, vascular 
disease -3%.
Causes of SE3: Idiopathic -30%., fever- 25%, acute symptomatic- 35%, 
remote symptomatic- 15%, progressive- 5%. Most common causes are AED 
withdrawal  or  non  compliance,  metabolic  disturbance,  drug  toxicity,  CNS 
infection, CNS tumor, Refractory epilepsy, head trauma, febrile.
Status epileptics definition 101,102,103,104: International Classification Of 
Epileptic  Seizures/  Conventional  “Textbook”  Definition  Of  Status 
Epilepticus 110:Continuous seizures activity lasting for 30 minutes or longer, or 
Intermittent seizures activity lasting for more than 30 minutes, from which the 
patient does not  regain consciousness105, 106.
 This  definition  has  been  repeated  in  most  articles  and  textbooks. 
However, there is nothing magic about 30 minutes. In fact, the likelihood for a 
tonic-clonic  seizure  to  stop  spontaneously  decreases  dramatically  after  5 
minutes.Where did the initial definition of 30 minutes come from?
WHY 30 MINUTES? :  Animal experiments in the 1970s and 1980s 
had shown that, neuronal injury could be demonstrated after 30 min of seizure 
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activity, even while maintaining respiration and circulation 6.Here the concepts 
of potential neuronal injury related solely to the duration of SE, is based in part 
of  animal  studies.  Despite  optimal  circumstances  during  SE,  with  animals 
paralyzed and ventilated, neuronal damage may occur after 30 minutes in pars 
reticularis  of  substantia  nigra,  and  after  45-60  minutes  in  hippocampus, 
thalamic nuclei, cerebellum purkinji cells, layer IV, V of the neocortex, and 
other parts subsequently.
In  1999  Lowenstein,  Bleck,  Macdonald  17 proposed  an  operational 
definition for GCSE in adults and older children (>5 years old) to incorporate 
the practical consideration of patient management. GCSE in adult and older 
children (>5years old) refers to > or = 5 minutes of a (a) Continuous seizure 
or(b)  Two  or  more  discrete  seizures  between  which  there  is  incomplete 
recovery of consciousness.
This determination was based in part of a study completed by Theodore 
et  al107 that  analyzed  120  GTCS  recorded  during  inpatient  monitoring  and 
reported mean seizure duration of 62 seconds. Because no seizures lasted for 
more than 2 minutes, more prolonged seizures encourage the development of 
SE and the need for IV therapy.
This determination excludes children <5 years because relatively little is 
known about the typical single seizure in this age group. Initial febrile seizures 
108 and acute symptomatic seizures in children can be prolonged but do not 
result  in  the same morbidity  seen in  adult  with prolonged seizures.  Further 
work  needed  in  this  age  group,  before  an  operational  definition  can  be 
formulated and treatment strategies developed. But majority of SE occurs in the 
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age group <5 years and we see more morbidity and mortality in younger age 
group (infants and young children).
This  operational  definition is  accepted worldwide16 in  the  emergency 
department   for  the management of  SE. So,  this  definition is  followed for 
selection of cases in this study. But because of paucity of reports for SE in 
younger  children  and  infants  and  no  operational  definitions  at  present 
formulated,  we have taken this  definition  for  children of  <5 years  also  for 
epidemiological purpose.
Practical  Definition:  SE refers  to  the  seizures  lasting  longer  than  5 
minutes or seizures on presentation to ER or recurring in the ER2. SE refers to 
continuous seizures or repetitive discrete seizures with impaired consciousness 
in the inter ictal period. The duration of seizure activity sufficient to meet the 
definition of SE has traditionally been specified as 15 to 30 min. However, a 
more practical definition is to consider SE, as a situation in which, the duration 
of  seizure  prompts  the  acute  use  of  anticonvulsant  therapy,  typically  when 
seizures last beyond 5 minutes 109.
Typical seizure duration: Children > 5 years: Typical, generalized tonic-
clonic seizure lasts < 5 minutes, Young children and infants: Paucity of data. 
Suggested time frame for typical tonic-clonic seizure, may be < 10-15 minutes. 
Patients  with  generalized  seizure  activity  at  arrival  in  the  ER  are  treated 
promptly regardless  of  prior  duration. The fact  that  infants  with SE have a 
higher mortality is likely due to the different etiologies of SE in infants, when 
compared to older children17. 
36
Data on outcome in SE is sparse in India. SE is one of the most common 
emergencies, we managed in our hospital and we see the largest number of SE 
in children, in our part of the country. As a tertiary level referral hospital, we 
managed those cases that were referred as refractory seizures. Many children 
come from long distances with prolonged SE. They do not have effective pre 
hospital therapy, proper referral and transport services.
Though we managed many SE successfully, we do come across poor 
outcome in SE. If the risk factors influenzing poor out come are identified, 
some of the factors can be modified and the high risk groups, who are going to 
have  poor  outcome  can  be  managed  aggressively  and  with  better  care  to 
improve their outcome.   
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AIM OF THE SYUDY
Aim  of  this  study  is  to  determine  clinical  profile,  and  immediate 
outcome of SE in children, managed in our hospital.
Secondary aim is to identify risk factors influenzing adverse outcome.
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STUDY DESIGN : Descriptive study.  
STUDY PEROID: : Jan 2005 -to –Dec 2005.
STUDY POPULATION : Children from 1 month to 12 years of age, 
who have been managed as SE were studied.
STUDY PLACE : Institute  of  Child  Health  and  Hospital  for 
Children, Chennai.8
INCLUSION CRITERIA : All  children  presented  with  SE  (including 
non  convulsive  SE  and  secondary 
generalized),  managed with anti convulsant 
as per the protocol in the above age group in 
ER
EXCLUSION CRITERIA : Seizures  controlled  before  arrival  to  the 
hospital or before starting IV therapy.
Simple partial SE: and other NCSE like myo 
clonic  SE  with  normal  vital  signs  and 
without loss of consciousness).
Seizures  occurred  during  hospital  stay,  
not at arrival 
SAMPLE  SIZE : Sample size was calculated based on a pilot 
study of 49 patients. Here the mortality was 
20%. From review of MRD records in ICH, 
average cases of SE were 25-30 per month 
and the  precision was fixed as  7%.  Hence 
with the α error of 5% the required sample 
size  statistically  calculated  for  the  least 
expected risk factor was 126.
SAMPLING TECNIQUE : All cases included over that period.
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DROP OUTS : Totally 131 cases were included. 4 drop outs 
(2 lost  follow up,  2 absconded).  127 cases 
completed the study.
DEFINITIONS
SE: Defined as > or = 5 minutes of a (a) Continuous seizure or (b) Two or 
more  discrete  seizures  between  which  there  is  incomplete  recovery  of 
consciousness.
CSE:  Refers to GTCS either primary or secondary to focal onset,  in which 
whole  or  part  of  the  body  muscles  having  visible  convulsions  (clonic 
movements) 
NCSE: Refers to persistent seizure activity (proved by intra ictal EEG), but no 
visible convulsions. Here they may have subtle signs of seizure activity such as 
unresponsiveness/ALOC  or  acute  confusional  state,  apnea,  defective  DEM, 
conjugate  deviation  of  eyes,  nystagmus,  twitching  of  eye  lids,   lipsmaking 
movements, dilated pupils, tachycardia, excessive secretions, hypertension.
NEURO EMD (ELECTRICAL SEIZURES):   No  visible  sign  of  seizure 
activity,  but  EEG shows ongoing  seizure  activity.  Example:  SE in  patients 
paralyzed with neuro muscular blockade.
INITIAL SEIZURE CONTROL:  Seizure control by drugs at the time of first 
contact with the ER.
CLINICAL CONTROL:  No  evidence  of  seizures  activity  such  as 
convulsions, apnea, unresponsiveness, defective DEM, conjugate deviation of 
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eyes, nystagmus, twitching of eye lids, lipsmaking movements, dilated pupils, 
tachycardia, excessive secretions, hypertension and 
a stable airway with intact protective reflexes, stable respirations, DEM+, with 
or without regaining of consciousness. 
GOOD RESPONSE:  Was defined as seizure activity  controlled with AED 
within 60 minutes of contact with hospital and initiation of therapy. That is 
controlled with first line drugs (BZD, phenytoin, phenobarbitone).
REFRACTORY SE:  Defined as if the duration of control of seizure activity 
was  more  than  1  hour  or  not  controlled  with  first  line  drugs 
(Lorazepam/Diazepam, Phenytoin, Phenobarbitone)
MORTALITY: Defined as death occurring in hospital during the course of 
treatment of SE irrespective of whether it was controlled or not
AMA: Means, discharged against medical advice during the treatment of SE 
without improvement and regaining baseline consciousness.
DURATION: Means, time starting from onset of that episode prior to arrival 
to hospital or starting from the onset of I episode of seizure, in case of more 
than one episode but   with impaired consciousness in between the series of 
seizures. 
HISTORY OF EPILEPSY: Defined as two or more unprovoked seizures in 
the past whether on treatment or not.
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FEBRILE CSE:  Status epilepticus associated with fever in a neurologically 
normal child between the ages of 6 months and 5 years is considered to have a 
good prognosis.
MANOEUVRE
Institutional consent and parental consent were obtained. First the cases 
were selected as per the inclusion criteria.  Each child had been assessed on 
arrival and a preliminary history was obtained and documented in a pre formed 
proforma. Rapid cardio pulmonary assessment was made at ER. Preliminary 
clinical  assessment  was  made.  It  included Sa02 at  arrival,  BP,  presence  of 
shock,  pupil  etc.  Before  starting  IV  therapy,  blood  sample  was  taken  for 
baseline investigations (sugar, calcium, and electrolytes). Then the cases were 
managed  according  to  the  protocol  followed  in  our  ER  and  admitted  in 
wards/PICU
There,  the cases  were reassessed and detailed history were obtained 
including duration of seizure, distance from the place where the fits occurred, 
mode of transport, pre hospital therapy, precipitating factors, prior seizures/SE, 
drug history  and compliance developmental  miles  stones,  prior  neurological 
status.  Complete  clinical  examination  was  made  including  neurological 
examination.  Relevant  investigations  were  done  like  CSF  analysis,  CT 
brain/USG cranium, EEG etc. Course of illness and therapy were monitored 
regularly till discharge. Time taken for control of refractory SE, time taken for 
full recovery of consciousness, requirement for prolonged ventilatory support 
(manual/  mechanical),  refractory  shock  or  subsequent  shock  following 
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midazolam or due to complications like sepsis, maximum dose and duration of 
ionotropes  and  midazolam  /  thiopentone  infusions,  recurrence  of  fits, 
complications  were noted.. Status of the child at the time of discharge was 
noted. They were followed for 1 month then the neurological status at the end 
of 1-month was re assessed. Their neurological status was  compared with the 
previous neurological status. 
Outcome  was  determined  by  the  following  variables:  Death,  AMA 
(persistent ALOC and unstable vitals till AMA), and new neurological sequele, 
complete recovery, no new neurological sequele (already existing). 
Observations were entered as tables and percentage charts. According to 
the  final  outcome  the  children  were  divided  into  two  groups.  Death,  new 
neurological  sequele,  AMA were  taken  as  poor  out  come group and those 
children  recovered  completely  or   recovered  without  any  new neurological 
sequele were taken as good outcome group.  Predictors of poor outcome were 
analyzed for  the following risk factors compared with good outcome group 
using univariate analysis and multivariate logistic regression. P value of < 0.05 
is taken as statistically significant. Odds ratio and 95% confident interval were 
also calculated for statistical significance.
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FOLLOWING  RISK  FACTORS  ANALYZED  FOR  PREDICTING  POOR 
OUTCOME:
           Age (<12 months),
Duration of seizure (>60 minutes),
Increasing distance
Type of seizure
Fever
Prior SE
Poor drug compliance
Developmental delay
Prior neurological abnormality
No pre hospital therapy
        Hypoxia at arrival
Refractory Shock
RSE
Prolonged respiratory failure (IPPV)
Inter ictal EEG abnormalities
Underlying cause of SE
CNS infections
Abnormal neuro developmental status before SE
Acidosis
Hypoglycemia at arrival
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Totally 131 cases were included in this study. 4 drop outs (2 absconded, 
and 2 lost follow up after discharge). So, 127 cases completed the study.
AGE AND SEX DISTRIBUTION:
Out of 127, male children were 70 and female children were 57. M: F ratio 
was 1.22:1. In this 29.1% cases (37/127) were < 1 year. 58.3% (74/127) of cases were 
less  than  3  years  and  81.2%  (103/127)  cases  were  <6  years.  30%  deaths  were 
observed in children of <1 year of age. Females were more than male children in >10 
years of age (4 vs. 2) and in other age groups M>F. Mean age was 3 years and 5 
months. Range was from 32 days to 12 years.   
Male Female Total
Frequency % Frequency % Frequency % Cum.%
<1year 21 16.5% 16 12.6% 37 29.1 % 29.1%
1-3 20 15.7% 17 13.4% 37 29.1 % 58.3 %
3-6 18 14.2% 11 8.7% 29 22.9 % 81.2 %
6-10 9 7.1 % 9 7.1% 18 14.2 % 95.3 %
>10years 2 1.5% 4 3.2% 6 4.7 % 100 %
total 70 55% 57 45% 127 100 %
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DURATION OF HOSPITAL STAY:
Mean duration of hospital stay was 6 days and 18 hours and maximum 
duration was 27 days, which was observed in one child who had RSE with 
prolonged respiratory failure and died on 27th day.54 children (42.5%) were 
discharged within 5 days after admission. 95 children (74.8%) were discharged 
within 10 days after admission. Prolonged hospital stay of >19 days observed 
in 5 cases. All were diagnosed to have RSE.
21
16
20
17 18
11
9 9
2
4
4
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< 1year 1-3year 3-6year 6-10year > 10year
Male Female
No. of hospital days (d)
54 42.5 42.5 42.5
41 32.3 32.3 74.8
21 16.5 16.5 91.3
6 4.7 4.7 96.1
5 3.9 3.9 100.0
127 100.0 100.0
< 5 days
5 - 9 days
10 to 14 days
15 -19 days
> 19 days
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
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ONSET OF SEIZURES:
 Fits  started in their  home for 116/127 cases (91.3%).  Fits  started in 
ICH-OPD for  9  children  (7%)  and  for  2  children  had  fits  while  traveling 
towards hospital. Out of 7 cases in which fits started at OPD, 6 had survived 
and one child died due to prolonged respiratory failure and refractory septic 
shock. Seizure duration of 8-15 minutes was noted in those cases from OPD 
before starting IV therapy.
REFERRAL AND TRANSPORT:  
75/127 children (59.1%) were coming directly with out any referral or 
treatment  before  arrival  to  ICH.  30/127  children(23.8%)  were  referred  by 
practicing private practioners.11 cases referred by private hospitals for varies 
reasons  (financial  constrainments,  for  further  management,  AMA discharge 
etc). Out of 11, 9 children had survived. Only 10 children (7.9%) were referred 
from government set up (GH,PHC). 73 children (57.5%) were taken by Auto, 
26  (20.5%)  children  by  Bus,  8  children  (6.3%)  by  Train&  Auto,  2(1.6%) 
children  by  two wheeler,  10 cases  (7.9%) by attenders  directly  and only  7 
children were transported by Ambulance with O2.
DISTANCE AND DURATION:
15 children (11.8%) were coming from <1 km distance from ICH. 93 
children (73.2%) were from Chennai surroundings within 50 kms distance. 25 
cases (19.7%) were coming from  very long distance that is >100 km from 
ICH, coming from varies parts of Tamil Nadu and Andra Pradesh. Out of them 
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20 children (80%) had seizure duration of more than or = 24 hours and 15 
children (60%) had poor outcome (13 children died, 1 went AMA and 1 had 
new neurological sequele).Out of 20 deaths 13 cases (65%) were from >100 
km distance.
Distance frequency % Cum.%
<1km 15 11.8% 11.8%
1-10 10 7.9% 19.7%
10-19 41 32.3% 52%
20-49 27 21.3% 73.2%
50-99 9 7.1% 80.3%
>99 25 19.7% 100%
TOTAL 127 100%
DURATION:
 Mean duration was 16 hours and 44 minutes. Maximum duration of 10 
days observed.  26 cases (20.5%) attended ER  within 30 minutes of onset of 
fits. 46 cases (31.5%) had seizure of < 60 minutes duration before arrival. 65 
children had seizure duration <2 hours before arrival. 40 children had seizure 
of > 2 hours but < 1 day duration. Remaining (22children-17.3%) had seizure 
of > 1 day duration and out of them, 9 cases were admitted in private hospitals  
and treated with more than 1 anti convulsant drugs before arrival to ICH. Out 
of  20  deaths  18  deaths  occurred  in  children  who  had  seizure  of  >  1  hour 
duration. Only 2 deaths occurred in children with seizure of < 1 hour duration 
and both of them had pneumonia, acidosis, shock and hypoglycemia at arrival 
prolonged respiratory failure and septic shock was the cause for death in both 
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children. No deaths are new sequele observed in FSE (19 cases), though 9 FSE 
had seizure duration of more than 30 minutes.
TYPE OF SEIZURES:
Convulsive SE accounts for 73.3% (93) of the total cases. GTCS was the 
commonest type seen in 91 cases (72%). Out of them 67 cases had primary 
GTCS and 24 cases  had initially  focal  onset  with  secondary  generalization 
(18.9%).  2  cases  of  multifocal  clonic  SE noted.  This  was  seen  in  younger 
infants of <6 months of age. 34 cases (26.7%) were in NCSE at arrival to ER. 
In this 17 cases (13%) were in NCSE from the beginning and 17 cases initially 
convulsing and later became non convulsive (13 cases GTCS to NCSE and 4 
cases Focal to NCSE). 
Type of SE Frequency % Cumm%
GTCS  (Primary) 67 52.8% 52.8%
NCSE 17 13.4% 66.1%
Focal  to  Secondary 
Generalization
24 18.9% 85%
Multi focal 2 1.6% 86.6%
GTCS to NCSE 13 10.2% 96.9%
Focal to NCSE 4 3.1% 100%
Total 127 100%
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NUMBER OF FITS:
63 cases had single seizure (49.6%), 22 cases had two episodes, 9 had 
three and 33 had many episodes with impaired alert ness in between. Longest 
duration of a single episode noted was 400 minutes. Mean duration of a single 
episode was 22 minutes.
PRE HOSPITAL THERAPY:
Pre hospital therapy was given in 45 children (35.4%). Remaining cases 
were not given any ACDs prior to arrival, though some of them were referred. 
Out of 45 children those who received pre hospital therapy only 16 children 
were given proper drugs and in proper route. Proper means IV/PR diazepam, 
IV  lorazepam,  IM  /IV  /PR  midazolam,  IV  phenytoin  infusion,  IV 
phenobarbitone  infusion.  Here  14  children  received  IV  diazepam  with 
53%
19%
2%
13%
10% 3% GTCS
Sec GTCS
Mult ifocal
NCSE
GTCS to NCSE
focal to NCSE
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phenytoin (9 cases) or without phenytoin (5 cases) then.  One child had IM 
Midazolam  and  one  infant  had  IV  Phenobarbitone.  Where  as  29  children 
(22.8%) received improper drugs or improper route or inadequate doses. Most 
common drug given was IM diazepam (7 cases) and next was IM phenytoin (4 
cases).  6 cases received some IM injections which were not documented.  2 
cases  received dexamethasone and one child  received glucose water  orally. 
Two  cases  received  rectal  ACDs  (one  was  clobazam  and  other  was 
phenobarbitone). None of the children received rectal diazepam.  
PRECIPITATNG FACTORS:
11 children (8.7%) had ALOC prior to seizures and out of them 9 had 
acute CNS infection. Fever was present in 80 cases (63%) out of which 19 
cases diagnosed as febrile SE and fever precipited seizures in 27 known seizure 
disorder children. Causes of fever include, pneumonia/LRI, sepsis, AWD, etc. 
proper
13%
improper
23%
not given
64%
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Other precipitating factors were vomiting 37,  trauma 4, toxin 5 (camphor   2, 
neem  oil  3),  drugs  3  (carbamazepine  1,  unknown  2),  hypocalcemia 
/hypoglycemia 2, shock 6, hypoxia 6 and unprovoked seizures seen in 21 cases 
(16.5%). In FSE 9 children had seizure of > or = 30 minutes.
Fever 80(63%)
Vomiting 37
Trauma 4
Toxin-neem oil, camphor 5
Drug over dose 3
AWD 17
LRI/ URI 14
Pneumonia 10
Poor drug compliance 14
Unprovoked 21
Stress/sleep deprivation -
HISTORY OF SEIZURES:
Present in 70 cases (55.1%).  57 cases (44.9%) presented as SE in their 
first episode of fits. Out of 70 children who had h/o prior seizures, 55 children 
(43.3%) had afebrile seizures and 15 children (11.8%) had febrile seizures. Out 
of  55  afebrile  seizures  39,  had  idiopathic  epilepsy  and  16  had  structural 
neurological disorder that is CP, MR, PMS, PES, CVA, neuronal migration 
disorder, neurocutaneous syndromes etc.  22 had previous SE and treated with 
ACDs.   Totally  33/127  had  CNS co  morbidity.  36/127  had  delayed  miles 
stones.  47/127 cases,  including both febrile  and afebrile  seizures (6 febrile, 
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41afebrile) were on AEDs. 16 children were on mono therapy and 31 children 
had > one drug to control fits. H/o poor drug compliance was present in 14 
cases and that could be the cause of SE in them.
CLINICAL STATUS AT ARRIVAL:
122/127 cases were apneic at arrival and needed BVM with 100% O2. 
5/127 had regular respirations and all the 5 were in NCSE and, so, O2 through 
non rebreathing mask was given. All children received supplementary O2 at 
arrival.  Mean  duration  of  BVM  was  29.5  minutes  and  maximum  was  75 
minutes. 44/127 children (35.4%) needed intubation and IPPV. Minimum of 2 
hours to maximum of 560 hours (26days) ventilatory support was given either 
by manual or by mechanical ventilator. Mean duration was 64 hours. 7 children 
needed IPPV for <7 hours and rest of them ventilated for >12 hours. 25 had 
poor outcome and 19 had good outcome in this group. 58 children had SaO2 of 
>92% at arrival and in remaining cases SaO2 was <92% and in 22 cases it was 
not recordable. 125/127 children had normal or high BP at arrival and 2 cases 
were brought with hypotensive shock and both of them died.
Shock was identified in 92/127 cases (72.4%). It was corrected with RL 
only in 54 cases (42.5%) and inotrope support needed in 38 cases (29.9%). 
Shock corrected at  ER in 12 cases those who needed inotropic support  and 
refractory shock seen in 26 cases (20.5%).
PUPIL 
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Pupil was normal in 81 cases (63.8%). Dilated pupil and  reacting to 
light was seen in 36 children and pupil was constricted and reacting to light in 
1 case. Sluggishly reacting dilated pupil seen in 3 cases and pupil was unequal 
(raised ICP) in 6 cases (4.7%). DEM defective in 118/127 children and DEM 
present in 9 cases.
PUPIL Frequency % Cumm %
PERL 81 63.8% 63.8%
Dilated reacting 36 28.3% 92.1%
Sluggishly reacting 3 2.4% 94.5%
Constricted 1 0.8% 95.3%
Unequal 6 4.7% 100%
Total 127 100%
MANAGEMENT OF FITS:
 2 cases received IM midazolam as the IV access could not be obtained 
and  fits  controlled  with  midazolam  in  one  case  and  with  subsequent  IV 
lorazepam in one case. None of the fits controlled with 25% dextrose alone 
though  13  cases  had  documented  hypoglycemia  at  arrival.  In  32  children 
(25.3%) fits  controlled with I  dose of  lorazepam and 26 cases (20.5%) fits 
controlled  with  II  dose  of  lorazepam.   In  26  cases  fits  controlled  with 
lorazepam  +  phenytoin  and  in  19  cases  with  lorazepam  +  phenytoin  + 
phenobarbitone.  2  children received calcium gluconate  as  they were  known 
cases of hypocalcemic seizures and in 2 children phenytoin was withheld, one 
child  already  received  adequate  dose  (30  mg/kg  IV infusion)  of  phenytoin 
before  arrival  to  ICH and one child had hypotension.  So,  in  109/127 cases 
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(85.8%) fits controlled with I line drugs and 18/127 cases needed midazolam 
infusion. 
RSE 
 18 children were considered to have RSE and out of them 10 survived 
(55.6%), 8 died (44.4%). All children were started on midazolam infusion with 
in 2 hours of hospitalization. Fits controlled with midazolam in 16 cases. Fits 
controlled in < or = 3 mcg /kg/ min in 10 cases and in < or = 6 mcg /kg /min in  
12 cases (66.67%). 6 cases (33.33%) needed higher doses of midazolam (9 mcg 
/kg /min to 25 mcg/ kg/ min). Minimum dose was 1 mcg/kg/min and maximum 
dose was 25 mcg/kg/min. Mean dose was 6.22 mcg/kg min. 2 children needed 
thiopentone infusion to correct  refractory SE. But for  both of them fits  not 
controlled with thiopentone also and subsequently died. 
MIDAZOLAM DOSE AT WHICH SEIZURES WERE CONTROLLED
DOSE NUMBER OF PATIENTS %
1-3 mcg /kg/ min 10/18 55.56%
4-6 mcg /kg /min 2/18 11.11%
> 6 mcg /kg/ min 6/18 33.33%
TOTAL 18 100%
Mean duration to control fits in those children was 4 hours 35 minutes. 
In 15 children (83.33%) fits controlled within 8 hours of starting midazolam 
infusion. In 13 cases (72.22%) midazolam given for < 2 days and in 17 cases 
(94.44%) it was given for <4 days.  Maximum duration of midazolam infusion 
was 500 hours but that child did not respond. Mean duration was 61 hour and it 
was  usually  tapered  after  12  to  24  hours  of  seizure  free  period.  No  cases 
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observed recurrence of seizures on tapering midazolam. Shock was noticed in 
11/18 cases of RSE. 8 cases had shock after starting midazolam infusion and 6 
needed ionotropes and 2 cases corrected with fluid boluses.
DURATION OF MIDAZOLAM INFUSION
NUMBER OF DAYS NO.OF PATIENTS %
<2 DAYS 13/18 72.22%
2-4 DAYS 4/18 522.22%
>4 DAYS 1/18 5.56%
TATAL 18 100%
 
All children needed IPPV before starting midazolam infusion, intubated 
with atropine 0.02 mg / kg and midazolam IV 0.2 mg/ kg. Neuro muscular 
blockade avoided as they may interfere with the clinical signs of recovery.
Time Taken To Control Seizures Completely After Midazolam
TIME NO.OF PATIENTS %
< 30 MIN 9/18 50%
30 MIN-2 HOURS 3/18 16.66%
2-8 HOURS 3/18 16.66%
>8 HOURS 3/18 16.66%
RECURRENT SEIZURES
Observed in 35 cases (27.6%). 21 cases had single recurrence (16.5%) 
and 14 children had multiple recurrence. Most of them were managed with IV 
diazepam  (13  cases)  and  by  increasing  the  dose  of  midazolam  infusion. 
Recurrence was seen in 5 children with RSE and 10 children those who died.  
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CONSCIOUS REGAINED
Consciousness  regained  in  104  cases.  Mean  duration  for  complete 
recovery of consciousness was 40 hours.  Minimum 1 hour to maximum 12 
days observed. 47 children (37%) had regained full consciousness within 10 
hours of hospital stay.
COMPLICATIONS
Respiratory failure necessitating prolonged ventilation was seen in 44 
children  (34.8%).  Pneumonia  at  arrival  was  noticed  in  10  cases  and  6 
developed pneumonia subsequently. DIVC was seen in 4 cases, raised ICP was 
in 6 cases, acute renal failure was in 3 cases, phenytoin toxicity even with the 
therapeutic doses was in 8 cases,  persistent and recurrent shock in 48 cases 
(37.8%) were some of the complications encountered. 2 children with normal 
lung before had pneumo thorax and it could be due to manual IPPV. No cases 
of hyperthermia,  rhabdomyolysis or diabetes insipedus were encountered.
Hypoglycemia at arrival was noted in 13 children and hyperglycemia in 
11 cases. Low HCO3 was seen in 19 cases and hypocalcemia in 11 cases. No 
case of hyper calcemia or hyper natremia was seen. 3 hypo natremias, 14 cases 
of hypokalemias, 1 case of hyper kalemia were observed.
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   DIVC 4
Pneumonia  at arrival 10
                 Later 6
ICP 6
ARF 3
Phenytoin toxicity 8
Pneumo thorax 5
Hyperthermia/ Rhabdomyolysis /DI -
Hypo natremia 3
Hypokalemia 14
Hypoglycemia 13
Hyperglycemia 11
Hyperkalemia 1
Low HCO3 19
CSF
LP and CSF analysis was done in 70 cases either antimortum or post 
mortum in case of death. Out of them, 54 children had normal CSF, 16 cases 
had abnormal CSF (elevated protein, decreased sugar, pleocytosis). 2 children 
had organisms in CSF.
CT/USG
CT brain was done for 56 cases and found to be normal in 35 cases and 
abnormal in 21 cases.  USG cranium was done in 39 cases and found to be 
normal in 31 cases. MRI was done in 4 cases to confirm the CT findings. CT 
brain was usually done in all cases of SE with focal onset of seizures (28 cases) 
and found to be  abnormal in 25 cases (89.2%)
EEG
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We were not able to do bedside EEG or EEG during seizures. Inter ictal 
EEG was done for 54 children. All cases of febrile SE were undergone for EEG 
(19 cases) and found to have normal EEG. 40 cases had normal EEG and 14 
had abnormal EEG.
FINAL DIAGNOSIS: 
42  children  were  diagnosed  to  have  acute  symptomatic  SE  (toxic 
encephalopathy-5, drug over dose -3, metabolic SE-2, Trauma-3, Acute CNS 
infection- 19, poorly identified acute encephalopathy- 1, septic shock-9).  19 
children were diagnosed as FSE and 22 children had idiopathic epilepsy . 43 
children fall in to remote symptomatic group (structural brain lesions, CP-34, 
PMS-1,  CVA-1,  neurocutaneous  -3,  others-4).  One  child  had  progressive 
degenerative disorder. 
Diagnosis Frequency % Deaths AMA New 
sequele
FSE 19 15.% 0 0 0
Idiopathic 22 17.2% 0 0 0
Remote  symptomatic  (CP 
/MR /DD/PMS/PES/FND)
43 33.8.% 5 1 0
 Progressive CNS degenerative 
conditions
1 0 .8% 0 0 0
Acute CNS infection 19 15.% 7 0 2
Toxic encephalopathy 5 3.9% 1 1 0
Trauma 3 2.4% 0 0 0
Septic shock 9 7.1% 5 1 0
Drug over dose 3 2.4% 0 0 0
Metabolic seizures          (hypo 
calcemia)
2 1.6% 1 0 0
Acute encephalopathy 1 0.8% 1 0 0
Total 127 100% 20 3 2
FINAL OUTCOME
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Out of 127 children 76 children (59.8%) recovered completely without 
any neurological sequele at the end of 1 month and they were on regular follow 
up  in  neuro  OPD.  26/127  children  (20.5%)  recovered  no new neurological 
sequele  as  compared  to  their  previous  status.  So,  totally  92  children  were 
(80.3%)  classified  into  good  outcome  group.  20  deaths  (15.7%)  observed 
during  this  study.  3  AMA  discharges  (2.4%)  noted.  They  were  all  on 
ventilatory support and ALOC till discharge. so they were also included in the 
poor outcome group. 2 children had new neurological sequele at the end of I 
month , one had hydrocephalus and other had hemi paresis which were not 
present already.
 The incidence of SE was more in male than female in this study 
(1.22:1) but it is not statistically significant.
 Age range from 32 days to 12 years; mean 3 years and 5 months. 
Nearly 81 % of the total cases were < 6 years of age. Around 30 % 
of the cases were < 1 year and 30 % of the total deaths were occurred 
in that age group. 85% of deaths were occurred in the age group of 
<3 years.  So, most of the cases of SE were younger children and 
mortality is also high in this group reflecting the underlying causes 
like acute CNS infection and septic shock are responsible than the 
seizures them selves.  
 Prolonged  hospital  stay  >19  day  observed  in  5  cases.  All  were 
diagnosed to have RSE. Mean duration of hospital stay was 6 days 
and  18  hours  and  maximum  duration  was  27  days,  which  was 
observed  in  one  child  who  had  RSE  with  prolonged  respiratory 
failure
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 Fits started in their home for 91% cases. Fits started in ICH-OPD for 
9 children (7%) and for 2 children had fits while traveling towards 
hospital. Out of 7 cases in which fits started at OPD, 6 have survived 
and one child died due to prolonged respiratory failure and refractory 
septic shock
 Nearly 60% children were coming directly with out any referral 
or treatment before arrival to ICH. 24% children were referred by 
near by practicing private practioners.11 cases referred by private 
hospitals  for  varies  reasons  (financial  constrainments,  for  further 
management,  AMA  discharge  etc).  Out  of  11,  9  children  have 
survived. Only 8% of the children were referred from government 
set up (GH, PHC).
 78%  of  children  were  taken  by  Auto  and  Train  and  only  7 
children (5.6%) were transported by Ambulance with O2.
 Nearly 50 % of the children had seizure duration of < 2 hours prior 
to arrival to ICH. Most of them were coming from near by places. 
20% came from long distance >100 km and they spent a lot of time 
in traveling and in pre hospital management. In nearly 80% of the 
cases long distance was responsible for prolonged duration of seizure 
and in remaining cases management of seizures in private hospital 
and other  clinic  or  PHC is  responsible.  Out  of  them 20  children 
(80%)  had  seizure  duration  of  more  than  or  =  24  hours  and  15 
children (60%) had poor outcome (13 children died, 1 went AMA 
and  1  had  new  neurological  sequele).Out  of  20  deaths  13  cases 
(65%)  were  from >100 km distance.  Out  of  20 deaths  18 deaths 
occurred in children who had seizure of > 1 hour duration. Only 2 
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deaths occurred in children with seizure of < 1 hour duration and 
both of them had pneumonia, acidosis, shock and hypoglycemia at 
arrival prolonged respiratory failure and septic shock were the cause 
for death in these children.
 No deaths observed in FSE (19 cases), though 9 FSE had seizure 
duration of more than 30 minutes.
 GTCS was the commonest seizure type (74%). NCSE accounts for 
26% of the cases.
 Pre hospital therapy was given in 45 children (35.4%). Remaining 
cases were not given any ACDs prior to arrival though some of them 
were referred. Out of 45 children those who received pre hospital 
therapy  only  16  children  were  given  proper  drugs  and  in  proper 
route. This includes IV/PR Diazepam, IV Lorazepam, IM /IV /PR 
Midazolam,  IV  Phenytoin  infusion,  IV  Phenobarbitone  infusion. 
Here 14 children received IV diazepam with (9 cases) or without (5 
cases) phenytoin infusion then. One child had IM midazolam and 
one infant  had IV phenobarbitone.  Where as 29 children (22.8%) 
received improper drugs or improper route or inadequate doses. Most 
common drug given was IM diazepam.  Two cases received rectal 
ACDs (one was clobazam and other was phenobarbitone). None of 
the children received rectal diazepam. 
 11 children (8.7%) had ALOC prior to seizures and out of them 9 
had acute CNS infection. Fever was present in 80 cases (63%) out of 
which  19  cases  diagnosed  as  febrile  SE  and  fever  precipitated 
seizures in known seizure disorder of 27 children.
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 Seizures were controlled with first line drugs in 86.8% and refractory 
SE in 18 cases(14.2%).
 RSE corrected with midazolam: 16 cases, 2 uncorrected and needed 
thiopentone. Midazolam dose: 1-25 mcg, mean 6.22 mcg, <6 mcg in 
10 cases, mean duration 61 hours. Max 500 h but not controlled.
 Consciousness regained in 104 cases.  Mean duration for complete 
recovery  of  consciousness  was  40  hours.  Minimum of  1  hour  to 
maximum of 12 days observed. 47 children (37%) had regained full 
consciousness within 10 hours of hospital stay.
 History of seizures was present in 55% cases. 45% were presented as 
SE in their first episode of fits itself. In children who had h/o fits, 39 
had idiopathic epilepsy and 16 had structural neurological disorder 
that is CP, MR, PMS, PES, CVA, neuronal migration disorder, neuro 
cutaneous syndromes etc.  22 had previous SE.  Totally 33/127 had 
CNS co morbidity. 36/127 had delayed miles stones. H/o poor drug 
compliance was present in 14 cases and that could be the cause of SE 
in them and in other cases SE is mostly precipitated by fever.
 122/127 cases were apneic at arrival and needed BVM with 100% 
O2. 5/127 had regular respirations and all the 5 were in NCSE and, 
O2  through  non  rebreathing  mask  was  given.  So,  all  children 
received supplementary O2 at arrival. Mean duration of BVM was 
29.5 minutes and maximum was 75 minutes. 69 cases (54.3%) had 
SaO2 <92% at arrival.
 44  Children  needed  IPPV.  Duration:  from  2  hrs  to-  560  hrs  (23 
days).  Ventilatory  support  was  given  either  by  manual  or  by 
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mechanical  ventilator.  Mean  duration  was  64  hrs.  25  had  poor 
outcome and 19 had good outcome in this group. So, all  children 
under poor out come were on IPPV.   
 92 cases (72.4%) had shock at arrival. 2 were hypotensive, both died, 
corrected in  66 cases.  In  21% cases  persistent  shock was present 
even with ionotropes at ER, Subsequent shock in nearly 37%.
 Pupil was normal (nearly 64% cases) or dilated and reacting to 
light  (28%  cases)  in  most  of  the  children  with  SE.  Pupil  was 
constricted and reacting to light in 1 case. Sluggishly reacting dilated 
pupil seen in 3 cases and pupil was unequal (raised ICP) in 6 cases 
(4.7%). DEM defective in 118/127 children and DEM present in 9 
cases.
 2 cases received IM midazolam as the IV access could not be 
obtained and fits  controlled with midazolam in one case and with 
subsequent IV lorazepam in one case.  None of the fits  controlled 
with  25%  dextrose  alone  though  13  cases  had  documented 
hypoglycemia at arrival. 
 In 89% of cases fits controlled with I line drugs and 18/127 cases 
needed midazolam infusion. These 18 children were considered to 
have RSE and out of them 10 survived (55.6%),   
 RSE:   All  children  were  started  on  midazolam  infusion.  Fits 
controlled with midazolam in 16 cases. Mean duration to control fits 
in  those  children  was  4  hours  35  minutes.  In  8  children  fits 
controlled within 8 hours of starting midazolam infusion. 2 children 
needed thiopentone infusion to correct refractory SE. But for both of 
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them fits not controlled with thiopentone also and subsequently died. 
Maximum duration of midazolam infusion was 500 hours but that 
child  did  not  respond.  Mean  duration  was  61  hour.  No  cases 
observed recurrence of seizures on tapering midazolam. Those who 
responded to  midazolam fits  controlled  in  <  6  mcg/kg/min  in  10 
cases and others required more for seizure control. In 2 cases those 
who did  not  respond to  either  midazolam or  thiopentone,  needed 
higher doses of midazolam (9 mcg /kg /min to 25 mcg/ kg/ min). 
Minimum  dose  was  1  mcg/kg/min  and  maximum  dose  was  25 
mcg/kg/min. Mean dose was 6.22 mcg/kg min. Shock was noticed in 
11 cases.  8 cases had shock after starting midazolam infusion and 6 
needed inotropes and 2 cases corrected with fluid boluses. 
 Seizure  recurrence  was  observed  in  28%  cases.16.5%  had  single 
recurrence and remaining had multiple recurrences.  Most of  them 
were managed with IV diazepam (13 cases) and by increasing the 
dose of midazolam infusion. Recurrence was seen in 5 children with 
RSE and in 10 children those who died.  
 Respiratory failure needs prolonged ventilation (35%) and persistent/ 
recurrent shock (38%) were the commonest complications noted in 
this  study.  Pneumonia,  DIVC,  raised  ICP,  acute  renal  failure, 
phenytoin toxicity even with the therapeutic doses were some of the 
complications encountered. 
 2 children had pneumo thorax with normal lung before and it could 
be due to manual IPPV. No cases of hyperthermia or rhabdomyolysis 
or diabetes insipedus were encountered.
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 Hypoglycemia at arrival was noted in 13 children and hyperglycemia 
in 11 cases. Hypoglycemia may be the cause of SE or consequence. 
None of the children responded to 25% dextrose alone so the cause 
of  hypoglycemia  in  this  study  was  due  to  the  consequence  of 
prolonged SE. Low HCO3 was seen in 19 cases and all were found 
to have metabolic acidosis by ABG. 3 hypo natremias, 14 cases of 
hypokalemias, 1 case of hyper kalemia, 11 cases of hypocalcemia 
No case of hyper calcemia or hyper natremia was seen..
 LP and CSF analysis was done in 70 cases either antimortum or post 
mortum in case of death. Out of them, 54 children had normal CSF, 
16  cases  had  abnormal  CSF  (elevated  protein,  decreased  sugar, 
pleocytosis). 2 children had organisms in CSF.
 CT brain was done for 56 cases and found to be normal in 35 cases 
and abnormal in 21 cases. USG cranium was done in 39 cases and 
found to be normal in 31 cases. MRI was done in 4 cases to confirm 
the CT findings. CT brain was usually done in all cases of SE with 
focal onset of seizures (28 cases) and it was abnormal in 25 cases 
(89.2%)
 We were not able to do bedside EEG or EEG during seizures. Inter 
ictal EEG was done for 54 children. All cases of febrile SE were 
undergone for EEG (19 cases) and found to have normal EEG. 40 
cases had normal EEG and 14 had abnormal EEG.
 FINAL DIAGNOSIS:   Most  common causes  of  SE were  remote 
symptomatic ( structural lesions) – 34%, idiopathic epilepsy- 17%, 
Acute  CNS  infections-  15%,  Febrile  SE-15%,  septic  shock-7%. 
Others  were  toxin,  drug  over  dose,  acute  encephalopathy, 
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progressive  degenerative  disorders,  metabolic  seizures.   Deaths 
mostly  occurred  in  acute  CNS  infection  7/20,  septic  shock-5/20, 
structural brain lesions-5/20. None of the death occurred in febrile 
SE and idiopathic epilepsy.
FINAL OUTCOME:
 Out  of  127  children  76  children  (59.8%)  recovered  completely 
without  any neurological  sequele at  the  end of  1 month and they 
were on regular follow up in neuro OPD. 26/127 children (20.5%) 
recovered no new neurological sequele as compared to their previous 
status.  So,  totally  92  children  were  (80.3%)  classified  into  good 
outcome  group.  20  deaths  (15.7%)  observed  during  this  study.  3 
AMA  discharges  (2.4%)  noted.  2  children  had  new  neurological 
sequele at the end of I month , one had hydrocephalus and other had 
hemi paresis which were not present already both were occurred in 
acute CNS infection. So totally 19.7% (25/127) of the cases were 
included in poor outcome group. 
RISK FACTORS DETERMINING POOR OUTCOME: 
Out of varies risk factors analyzed for predicting poor out come, Age < 
1 year, increasing distance from the place of onset, duration >1 hour, no proper 
pre hospital therapy, SaO2 of <92% at arrival, refractory shock in ER that is 
uncorrected even after starting ionotropes, on IPPV, refractory SE, acidosis at 
arrival  that  is  low HCO3 and supported  by  academia  in  ABG,  acute  CNS 
infection as the underlying cause if SE were some of the risk factors we found. 
Odds ratio, 95% confident interval, P values were calculated for poor out come 
group comparing with good outcome group and univariate analysis was done 
for all these risk factors.
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 Of all  the risk factors above mentioned age <1 years and < 6 years 
(p=0.05),  refractory  shock  (P=0.07)  were  not  statistically  significant  to 
influence the outcome adversely. Increasing distance (that is each Km increase 
in distance increases the odds ratio by 1.7), duration of > 1 hour, no proper pre 
hospital therapy, SaO2 < 92% at arrival,  acidosis at arrival,  need for IPPV, 
refractory SE, acute CNS infection were significant risk factors.  
Finally at the end of multiple logistic regressions of all the risk factors, 
only 4 factors namely increasing distance from the place of onset of seizures  to 
ICH, duration of seizures, need for IPPV, acute CNS infection as the etiology 
are  statistically  significant  risk  factors.  They  are  independent  risk  factors 
influenzing poor outcome.
Incidence  of  SE  among  male  children  is  more  (55%)  than  female 
children (45%) in this  study and the  male  predominance is  not  statistically 
significant (p>0.05) and male, female distribution is equal in other studies also. 
Mean age is 3 years and 5 months observed in this study where as mean age of 
SE is 2 years and 4 months noted in Mah JK et al 89 study, and Mean age of 
56.6 ±   46.5 months observed in Kalra Veena et al 97 study. Most of the cases 
of SE in children occurred in younger age group.
In our study nearly 60% of the cases were < 3 years and 82% were < 6 
years. Garzon E 84 observed that SE incidence peaked in the first years of life, 
and 56.7% cases were < 5 years in Kalra Veena 97 study. Mortality is also high 
in this age group. 85% of mortality occurs in the age group of < 3 years.
Outcome is determined by age, duration and underlying cause. Age < 1 
year,  duration of >1 hour,  acute CNS infection as the underlying cause are 
predictors of poor outcome seen in varies studies. Young age <12 months and 
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duration >60 minutes associated with adverse outcome concluded in Kwong et 
al  83 study,  deaths were correlated to etiology and patient’s age concluded in 
Garzon E  84 study, the group with SE lasting <1hr had a lower mortality as 
compared with seizure duration > or = 1 h observed  in  Towne AR et al  85 
study. Sahin et al 87 concluded that the mortality in RSE was related to etiology 
age and EEG findings and predictors of poor outcome were older age (OR = 
1.04,95% CI 1.01 – 1.07), delay in treatment ( OR = 9.73,95% CI 1.58 – 59.96) 
and CNS infection 9 OR = 30.27 95% C 3.14-292.19) seen in Hui AC et al 88 
study. Outcome related to etiology, duration, and age is a minor factor
Observed in  Dunn DW 90 study, mean seizure duration was 1.5 ± 2.8 hours in 
those children with a normal outcome, 1.7 ± 1.2 hours in those survivors with 
an abnormal neurological outcome (P > 0.05), and 6.8 ± 12 hours in those who 
died (P < 0.05) and both the duration and etiology of status epilepticus affect 
the outcome concluded by Simon J et al 92.
 Singhi S et al 94 concluded that the morbidity and mortality are highest 
with SE that associated with CNS infections which is the most important cause 
of SE in our country and the outcome depends on the underlying etiology, age, 
rapidity of SE and adequacy of care. He also opined that adherence to a time 
framed  protocol  in  the  ED  helps  in  improving  the  final  outcome.  Seizure 
duration  >45  min  (p.0.001),and  presence  of  septic  shock  (  p-0.001),were 
associated with significantly more mortality observed  in Kalra veena et al 97 
study. Young age < 12 months duration of seizure > 60 minutes are associated 
with adverse outcome seen in  Horn drop  study where as risk factors were 
age< 36 months and  refractory SE concluded by Shinner et al.
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In our study also duration > 1 hour, increasing distance from the place of 
seizure onset, acute CNS infection, need for IPPV were significant independent 
risk factors that predict poor out come. 
Commonest seizure type is GTCS and NCSE accounts for 20 % of SE. 
In our study also commonest seizure type is GTCS and NCSE account for 26% 
of SE. This may be because prolonged CSE in many cases (13.3%) resulted in 
NCSE due to neuro electro mechanical dissociation.
Proper pre hospital therapy is associated with good out come observed 
in this study.  No or improper pre hospital therapy is a significant risk factor for 
poor outcome in univariate analysis. Kwong et al 83 concluded that Pre hospital 
Rx with BZD reduces adverse outcome.  Allredge BK et al 92 also concluded 
that, Pre hospital therapy was associated with shorter duration of SE (P=0.007), 
reduced  likelihood  of  recurrent  seizures  in  ER  (P=0.045),  no  significant 
difference between PR and IV and simplify the subsequent  management  of 
these patients.
 In this study, 57 cases (44.9%) presented as SE in heir first episode of 
fits which is comparable with other literatures 2 and out of them, H/o poor drug 
compliance was present in 14 cases and that could be the cause of SE in them 
where as 59.4% of the individuals had pervious epilepsy while 40.6% had not 
in Garzon et al  84 study and 43% has no prior SE in Mah JK et al  90 study, 
28/60(46.6%) were no h/o prior fits in  Dunn DW et al  91 study, 16 patients 
(53.3%) had SE I episode with out prior H/o fits in Kalra veena et al 97 study.
Most  of  them  were  apneic  (122/127)  at  arrival  and  100%  needed 
supplementary O2 either BVM with 100% O2 or O2 through non rebreathing 
mask in this study. O2 through non can be given only when the respiration is 
regular and adequate only in case of NCSE because all CSE cases and most of 
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the  NCSE  cases  the  respiratory  muscles  also  involved  in  seizure  activity 
resulted in apnea. Apnea is not the contra indication for giving ACDs but is an 
indication for  initiating BVM in them.   Most  of  them were presented with 
shock also and needed fluid boluses and ionotropes support but nearly 20% of 
cases the shock left uncorrected in ER needed prolonged inotropic support. In 
hemo dynamically unstable patients, phenytoin should be used cautiously or it 
can be substituted with other ACDs. Fos phenytoin is found to be safe in these 
patients but it was not used as an ACD in this study. Commonest side effect 
observed after  stating phenytoin infusion was shock and hypotension rarely 
arrhythmias  needed  ionotropes  support.  Frequent  monitoring  of  BP  and 
HR/rhythm perfusion status is must. Preferably phenytoin is avoided in young 
infants of <3 months. 2 cases were found to have hypotension at arrival and 
subsequently died. 
 The incidence of RSE is 15% in this study where as 11.3% in Garzon et 
al 84 study, 26/418 in a previous study conducted in ICH by Santhosh Paulin96.
 Mortality  in  this  study  is  15.7%  which  is  comparable  with  many 
international as well as Indian literatures 3, 4, 5. Kalra veena et al 97 showed 30 
% mortality and  Garzon E 84 showed 19.5% and Hui AC et al 89 showed 26% 
mortality, where as 5.6 % mortality was observed by Simon J et al  93 and 3-
10% mortality was observed in Indian children as per  Singhi S et al  95 study 
and 4-6 % in US 2 
Etiology of SE:  FSE 15%, remote symptomatic34%, idiopathic epilepsy 
17%,  acute  CNS  infection  15%,  septic  shock  7%,  acute  metabolic/toxic 
encephalopathy 7%, others 5% were observed in this study.
Etiology 100: Fever – 36% (non –CNS infection), idiopathic - 24 – 39%, 
chronic neurological disease- 15%, metabolic /toxic- 8%, medication change 
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-20%, anoxia -5%, CNS Infection -5%, tumor-1%, acute trauma / abuse - 4%, 
degenerative disease- 2%, vascular disease -3%. 
Causes of SE 3: Idiopathic -30%., fever- 25%, acute symptomatic- 35%, 
remote symptomatic- 15%, progressive- 5%. Most common causes are AED 
withdrawal  or  non  compliance,  metabolic  disturbance,  drug  toxicity,  CNS 
infection, CNS tumor, Refractory epilepsy, head trauma, febrile SE.
CNS infection is more common in our setup but it  is low in western 
countries (5%) due to the implementation of Hib, Pneumococal vaccination and 
improvement in quality of life style, environmental sanitation and safe water 
supply. We come across only 2 new neurological sequele during this study. 
Both  were  due  to  acute  CNS  infection.  18/114  new  neurological  deficit 
observed in Dunn W 91 study and 17/193 new neurological deficits occurred in 
Maytal J et al 98 study.
 Mortality in SE in this study is 15.7% . Higher mortality in this study 
is mainly due to the underlying cause than SE itself.  Most of the 
cases of SE were young children of <6 years of age and mortality is 
also high in young children of <3 years who had 85% mortality. But 
there is no clear cut definition of SE is formulated in this age group 
till now.  
 There is no significant sex difference. 
 Commonest seizure type is GTCS. But NCSE also accounts for 26% 
of the cases. 
 All were required supplementary oxygen at arrival and most of them 
were apneic, hypoxic and shocky. 
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 9% of the children had hypoglycemia and 11% had hyper glycemia 
at arrival but all of them received 25% dextrose. 
 Common  causes  of  SE  are  acute  CNS  infection,  septic  shock, 
idiopathic epilepsy, febrile SE and CNS co morbidity like CP. 
 Febrile  SE  and  idiopathic  epilepsy  were  associated  with  good 
prognosis.  All  the  children  in  FSE  group  recovered  completely 
without any sequele. CNS infection and septic shock were associated 
with poor outcome. New neurological sequele occurred in 2 cases 
both of them had acute CNS infection as the underlying etiology. 
Long term outcome in these survivors need to be evaluated further.  
 Acute  CNS  infection,  duration  of  SE,  distance  travelled  to  seek 
medical  advice  and  respiratory  failure  requiring  IPPV,  are 
independent risk factors that influence the outcome adversely. 
 109 /127 cases responded to I line ACDs. 18 cases diagnosed as RSE 
and out of them 10 survived. Refractory SE is associated with poor 
outcome and prolonged hospital  stay.  Most  of  them responded to 
midazolam and only 2 cases required thiopentone but not controlled 
with  thiopentone  also.  All  cases  of  RSE  were  intubated  using 
midazolam IV as the sedative and neuromuscular blockade avoided. 
Common complication  of  midazolam infusion is  shock and noted 
only with higher doses >6 mcg/kg/min and managed with ionotropes. 
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1. Common cause of SE in our part of the country is acute CNS infection 
and this  results  in  higher  mortality,  morbidity  and later  neurological 
sequele. Acute CNS infection is one of the independent risk factor for 
poor outcome in SE. Vaccinating with Hib, Pneumococcal vaccines and 
prompt use of antimicrobial therapy in suspected cases to be undertaken 
to prevent acute CNS  infection.
2. Duration  and  distance  travelled  to  seek  medical  advice  are  also 
important risk factors influenzing poor outcome. So, early institution of 
proper time framed therapy even by the nearest hospital will improve 
the  outcome.  At  least,  proper  pre  hospital  therapy  like  the  use  of 
IM/PR/IV Midazolam or IV/PR diazepam and taking care of airway and 
breathing with supplementary O2 while transporting the child from the 
peripheries could result in better outcome in SE children.
3. Many  of  the  complications  and  consequences  can  be  managed 
successfully  with  anticipation  and  early  intervention  like  shock, 
respiratory  failure,  aspiration  pneumonias,  hypo/hyper  glycemias, 
dyselectrolytemias.
4. A bed side EEG will be useful in managing NCSE as the electrical SE or 
neuro  EMD  are  also  associated  with  same  neuronal  damage  and 
mortality as CSE. Even if EEG  is not available a high index of  clinical 
suspicion  of  NCSE  should  be  there  to  identify  ongoing  seizures  in 
partially treated comatose children. The clinical signs such as persistent 
apnea,  unresponsiveness,  defective  DEM,  nystagmus,  conjugate 
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deviation,  excessive  secretions  and  disproportionate  tachycardia  are 
some of the very important clues in identifying NCSE.
5. Management  of  vital  signs  and  underlying  cause  of  SE  along  with 
specific ACD therapy are the priorities in the management of SE.   
6. Midazolam is safe and effective for the treatment of RSE in children in 
our country.
75
ANNEXURE: PROFORMA
Serial No:
Hospital No:
Ward admitted:
Name:
Age; years:     .months:
Sex: M/F
Addresses
Phone no:
DOA: 
DOD: 
No of days in hospital: 
Time of arrival to ER: 
Fits started at;  
1. Home
2. OPD
3. While traveling
4. Pvt hospital
5. GH
6. Others
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Referred from:
1.No (self)
2. PHC
3. GH
4. PVT clinic
5. Pvt. Hospital
6. OPD
Distance from onset to ICH:
I. <1
II. 1-9 
III. 10-49
IV. 50-99
V. >100
Mode of transport:
1. hand
2. auto
3. car
4. two wheeler
5. ambulance
6. others
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Duration of seizure prior to reaching ICH;  in minutes:
Type of seizure:
1, GTCS:
2. Non convulsive:
3. Secondary generalization:
4. Others:
Number of attacks:
Each lasted for: in minutes: ---/---/---
Risk factors:  /sleep deprivation/stress/trauma/toxin/drugs/unprovoked/medical 
illness (specify-----------------)
Level of sensorium between attacks: ALOC/normal
H/o fever:    Yes/No; Duration:
H/o ALOC before fits Yes/No
H/o head trauma Yes/No
H/o Toxins/Drugs ingestion Yes/No
Pre hospital therapy: Yes/No
What drug: Route:
1. Diazepam
2. Lorazepam
3. Others. 
4. Not known
PAST HISTORY:
Past H/o seizure: Present/absent
Febrile/ Afebrile
Date of last episode;
H/o SE: Yes/No
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If yes, date of occurrence:
Duration:
Treatment given:
On AED:  Regularly or not
Which drug
Dose and duration
Compliance:  good/poor
Last dose:
Developmental history: Normal/delayed
Neurological status before SE: Normal/abnormal.
If abnormal specify:
Co morbid conditions: 
1.
2.
3.
4.
CLINICAL EXAMINATION:
Appearance: A/V/P/U
Breathing: required BVM Yes /No, how long: (min):
Required intubation Yes/No: how long (min):
Sa02 at arrival: 
Circulation: Shock: Yes/No
If yes: compensated/ decompensated
 BP at arrival: mm/hg
Requiring fluids/ requiring ionotropes /Uncorrected
Pupils:
Glucose:
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Calcium:
Na+:
K+:
HCO3-:
MANAGEMENT OF SEIZURES:
25% Dextrose/ Lorazepam/ BZD+ Phenytoin/Required PB
Refractory seizure:
IMCU:
Ward:
Midazolam / Thiopentone/ Others: yes/no
Maximum rate:
 How long
 Subsequently developed shock:  yes/no:
Time taken for full recovery of consciousness:  hours
Complications:
1. Acidosis
2. Pneumonia
3. Respiratory failure
4. ICP
5. Shock
6. Hyper thermia
7. Rhabdo myo lysis
8. Neuro logical deficit;
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Neurological examination: 
First at discharge 1 month
GCS: 
HF:
Cranial nerve
Pupil
Fundus:
Motor:
Involuntary 
Movements
sensory:
others:
developmental:
INVESTIGATIONS:
Hb:
TC:
DC:
PCV:
Platelets:
PSS:
Urea:
Creatinine:
Urine screening:
NEC:
CXR:
LFT:
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CSF analysis:
USG Cranium:
CT Brain:
EEG:
Final diagnosis: 
Outcome: 
1. Death:
2. New neurological sequele:
MR:
FND:
Extra pyramidal:
3. AMA
4. No New Neurological Sequele
5. Recovered.
82
SE: STATUS EPILEPTICUS
CSE: CONVULSIVE STATUS EPILEPTICUS
RSE: REFRACTORY STATUS EPILEPTICUS
NCSE: NON CONVULSIVE STATUS EPILEPTICUS
ASE: ABFENT STATUS EPILEPTICUS
PCSE: PARTIAL COMPLEX STATUS EPILEPTICUS
IPPV: INTERMITTENT POSITIVE PRESSURE VENTILATION.
CNS: CENTRAL NERVOUS SYSTEM
AED: ANTI EPILEPTIC DRUGS
ACD: ANTI CONVULSANT DRUGS
GABA: GAMMA AMINO BUTERIC ACID
EEG: ELECTRO ENCEPHALOGRAM
NMDA: N - METHYL D - ASPARTATE
GTCS: GENERALIZED TONIC CLONIC SEIZURES
CVA: CEREBRO VASCULAR ACCIDENTS
GCSE: GENERALIZED CONVULSIVE SE
BZD: BENZODIAZEPENES
LP: LUMBAR PUNCTURE
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